MAM
FATE icon

Martingale Asset Management’s Fate Therapeutics FATE Stock Holding History

Martingale Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34,797
Closed -$122K – 791
2024
Q3 		$122K Hold
34,797
– – ﹤0.01% 779
2024
Q2 		$114K Buy
34,797
+887
+3% +$3.88K ﹤0.01% 777
2024
Q1 		$249K Buy
+33,910
New +$210K 0.01% 737

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Martingale Asset Management's FATE Position: Q4 2024 in Review

Martingale Asset Management sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 34,797 shares — an estimated $122K sold.

Martingale Asset Management first reported a position in FATE in Q1 2024 and held it in 3 quarters. The position peaked at $249K in Q1 2024. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Martingale Asset Management reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Martingale Asset Management sold 34,797 Fate Therapeutics shares in Q4 2024, an estimated $122K.
  • Martingale Asset Management first reported a position in Fate Therapeutics in Q1 2024 and held it in 3 quarters.
  • Martingale Asset Management's Fate Therapeutics position peaked at $249K in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Martingale Asset Management's 13F filing for Q4 2024, filed 13 Feb 2025.